April 29, 2019
Medpace Holdings, Inc. Reports First Quarter 2019 Results
Revenue of $200.7 million in the first quarter of 2019 increased 23.1% from revenue of $163.1 million for the comparable…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
April 29, 2019
Beam Therapeutics Presents Data on Multiplex Base Editing for Engineered CAR-T Cells at American Society of Gene and Cell Therapy 22nd Annual Meeting
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, today announced the presentation of preclinical…
April 29, 2019
GlycoMimetics Bolsters Executive Team with Appointment of Dr. Eric Feldman as Vice President, Clinical Development, and Christian Dinneen-Long as Vice President, Corporate Counsel
Eric Feldman, M.D.,a specialist in leukemia and bone marrow disorder therapies, has beenappointed Vice President of Clinical Development GlycoMimetics.
April 29, 2019
Global Erectile Dysfunction (ED) Drugs Market 2019-2023 – Rising Demand for ED Drugs / Side Effects of Available Drugs / Competitive Landscape – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Erectile Dysfunction (ED) Drugs Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering. The erectile dysfunction (ED)…
April 29, 2019
Pfizer Receives Positive CHMP Opinion for TALZENNA® (talazoparib) for Patients with Inherited (Germline) BRCA-Mutated Locally Advanced or Metastatic Breast Cancer
Pfizer has received positive opinion recommending TALZENNA (talazoparib), an oral poly (ADP-ribose) polymerase (PARP) inhibitor
April 29, 2019
Alexion Receives Positive CHMP Opinion for ULTOMIRIS® (ravulizumab) in Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
ULTOMIRIS has the potential to become the new standard of care forboth complement inhibitor-naïve patients and patients switching fromSOLIRIS (eculizumab) –
April 29, 2019
New Genentech Data at the 2019 AAN Annual Meeting Showcase Breadth and Promise of Neuroscience Portfolio
New data will be presented for risdiplam, an investigational oralsurvival motor neuron 2 (SMN2) splicing modifier for SMA, which isdesigned to increase and sustain SMN protein levels in the centralnervous system (CNS) and throughout the body.
April 29, 2019
Global $3.28 Billion Probiotic Supplements Market (2018-2027): Development of Dry Probiotic Supplements for Chronic Diseases will Fuel Growth at an Expected CAGR of 10.15% During 2018-2027 – ResearchAndMarkets.com
Based on the source, the market was dominated by the bacteria-basedprobiotic supplements segment, with a 91% share in 2017. Most probioticsupplements include bacterial strains, of which, Lactobacillus sp andBifidobacterium sp are used widely for the maintenance of healthymicrobiota.
April 26, 2019
AVROBIO Highlights the plato™ Platform and Gaucher and Cystinosis Programs at the 2019 Annual Meeting of the American Society of Gene and Cell Therapy
CAMBRIDGE, Mass.–(BUSINESS WIRE)–AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced the participation of its…
April 26, 2019
New Data from Phase 3 Teprotumumab Trial (OPTIC) Shows Dramatic Reduction in Proptosis, or Eye Bulging, the Main Cause of Morbidity in Active Thyroid Eye Disease (TED)
New Data at the 2019 American Association of ClinicalEndocrinologists (AACE) Scientific and Clinical Congress DemonstratesSignificant Proptosis Reduction and Improvement in Overall Response Rate